VU-1545 demonstrates significant bioactivities across a range of biological targets and systems. It shows notable affinity for the mGluR5 receptor, with a Ki value of 160.0 nM, suggesting competitive binding, and an EC50 value of 9.6 nM in enhancing glutamate-induced calcium flux in rat astrocytes, indicating its modulatory effect on receptor signaling. In addition to mGluR5, VU-1545 exhibits various biopotencies, including moderate activity in mitochondrial dynamics, lipid storage modulation, strong inhibition against AmpC Beta-Lactamase, ELG1-dependent DNA repair, and delayed death inhibition of the malarial parasite plastid. It also shows potential as an inhibitor of Nrf2, TGF-b, Hepatitis C Virus (HCV), GLP-1 receptor inverse agonist, human TDP1, and stage-specific inhibition of Vaccinia Orthopoxvirus.
In antiviral assays, VU-1545 inhibits SARS-CoV-2 induced cytotoxicity in Caco-2 cells by 9.16% at 10 µM concentration after 48 hours and shows potential inhibition of SARS-CoV-2 3CL-Pro protease by -2.219% at 20 µM. It also demonstrates activity in reducing SARS-CoV-2 induced cytotoxicity in VERO-6 cells by 0.36% at 10 µM concentration after 48 hours.
Further, VU-1545 shows an inhibitory effect on human HDAC6 enzymatic activity, with 73.61% inhibition using a commercial peptide substrate. It impacts cell viability variably in HEK293T and U2OS cell lines, promoting growth, whereas it has mixed effects on human fibroblast cells. VU-1545 also affects the thermal stability of different molecular domains, either stabilizing or destabilizing them to varying extents.
Moreover, it is active in GPCR β-arrestin recruitment assays with multiple targets, including GPR119, APLNR, ADRB2, FPR2, GLP1R, CX3CR1, AGTR1, ADGRF1, S1PR1, C5AR1, FFAR4, GPR35, and ADRA2A, showing diverse levels of activation and inhibition. This broad spectrum of activity highlights VU-1545's potential as a versatile bioactive molecule with applications in various therapeutic areas..
Note: Summary generated by AI. Data source: ChEMBL 